Patent Publication Number: US-2004048339-A1

Title: Human proteins having transmembrane domains and cDNAs encoding these proteins

Description:
TECHNICAL FIELD  
       [0001] The present invention relates to human proteins having transmembrane domains and cDNAs coding for these proteins as well as eucaryotic cells expressing said cDNAs. The proteins of the present invention can be employed as pharmaceuticals or as antigens for preparing antibodies against said proteins. The human cDNAs of the present invention can be utilized as probes for the gene diagnosis and gene sources for the gene therapy. Furthermore, the cDNAs can be utilized as gene sources for large-scale production of the proteins encoded by said cDNAs. Cells, wherein these membrane protein genes are introduced and membrane proteins are expressed in large amounts, can be utilized for detection of the corresponding ligands, screening of novel low-molecular pharmaceuticals, and so on.  
       BACKGROUND ART  
       [0002] Membrane proteins play important roles, as signal receptors, ion channels, transporters, etc. in the material transportation and the information transmission which are mediated by the cell membrane. Examples thereof include receptors for a variety of cytokines, ion channels for the sodium ion, the potassium ion, the chloride ion, etc., transporters for saccharides and amino acids, and so on, where the genes of many of them have been cloned already.  
       [0003] It has been clarified that abnormalities of these membrane proteins are associated with a number of hitherto-cryptogenic diseases. For instance, a gene of a membrane protein having twelve transmembrane domains was identified as the gene responsible for cystic fibrosis [Rommens, J. M. et al., Science 245: 1059-1065 (1989)]. In addition, it has been clarified that several membrane proteins act as receptors when a virus infects the cells. For instance, HIV-1 is revealed to infect into the cells through mediation of a membrane protein fusion having a membrane protein on the T-cell membrane, a CD-4 antigen, and 7 transmembrane domains [Feng, Y. et al., Science 272: 872-877 (1996)]. Therefore, discovery of a new membrane protein is anticipated to lead to elucidation of the causes of many diseases, so that isolation of a new gene coding for the membrane protein has been desired.  
       [0004] Heretofore, owing to difficulty in the purification, many membrane proteins have been isolated by an approach from the gene side. A general method is the so-called expression cloning which comprises transfection of a cDNA library in eucaryotic cells to express cDNAs and then detection of the cells expressing the target membrane protein on the membrane by an immunological technique using an antibody or a physiological technique on the change in the membrane permeability. However, this method is applicable only to cloning of a gene of a membrane protein with a known function.  
       [0005] In general, membrane proteins possess hydrophobic transmembrane domains inside the proteins, wherein, after synthesis thereof in the ribosome, these domains remain in the phospholipid membrane to be trapped in the membrane. Accordingly, the evidence of the cDNA for encoding the membrane protein is provided by determination of the whole base sequence of a full-length cDNA followed by detection of highly hydrophoblc transmembrane domains in the amino acid sequence of the protein encoded by said cDNA.  
       DISCLOSURE OF INVENTION  
       [0006] The object of the present invention is to provide novel human proteins having transmembrane domains and DNAs coding for said proteins as well as transformation eucaryotic cells that are capable of expressing said cDNAs.  
       [0007] As the result of intensive studies, the present inventors have been successful in cloning of cDNAs coding for proteins having transmembrane domains from the human full-length cDNA bank, thereby completing the present invention. In other words, the present invention provides human proteins having transmembrane domains, namely proteins containing any of the amino acid sequences represented by Sequence Nos. 1 to 6. Moreover, the present invention provides DNAs coding for the above-mentioned proteins, exemplified by cDNAs containing any of the base sequences represented by Sequence Nos. 7 to 12, as well as transformation eucaryotic cells that are capable of expressing said cDNAs.  
     
    
    
     BRIEF DESCRIPTION OF DRAWINGS  
     [0008]FIG. 1: A figure depicting the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP00936.  
     [0009]FIG. 2: A figure depicting the hydrophobicty/hydrophilicity profile of the protein encoded by clone HP01535.  
     [0010]FIG. 3: A figure depicting the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10089.  
     [0011]FIG. 4: A figure depicting the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10216.  
     [0012]FIG. 5: A figure depicting the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10420.  
     [0013]FIG. 6: A figure depicting the hydrophobicity/hydrophilicity profile of the protein encoded by clone HP10441. 
    
    
     BEST MODE FOR CARRYING OUT THE INVENTION  
     [0014] The proteins of the present invention can be obtained, for example, by a method for isolation from human organs, cell lines, etc., a method for preparation of peptides by the chemical synthesis, or a method for production with the recombinant DNA technology using the DNAs coding for the transmembrane domains of the present invention, wherein the method for obtainment by the recombinant DNA technology is employed preferably. For instance, in vitro expression of the proteins can be achieved by preparation of an RNA by in vitro transcription from a vector having one of cDNAs of the present invention, followed by in vitro translation using this RNA as a template. Also, recombination of the translation region into a suitable expression vector by the method known in the art leads to production of a large amount or the encoded protein by using prokaryotic cells such as  Escherichia coli, Bacillus subtilis , etc., and eucaryotic cells such as yeasts, insect cells, mammalian cells, etc.  
     [0015] In the case in which a protein of the present invention is produced by a microorganism such as  Escherichia coli  etc., a recombinant expression vector bearing the translation region in the cDNA of the present invention is constructed in an expression vector having an origin, a promoter, a ribosome-binding site, a cDNA-cloning site, a terminator etc., which can be replicated in the microorganism, and, after transformation of the host cells with said expression vector, the thus-obtained transformant is incubated, whereby the protein encoded by said cDNA can be produced on a large scale in the microorganism. In this case, a protein fragment containing an optional region can be obtained by carrying out the expression with inserting an initiation codon and a termination codon in front of and behind an optional translation region. Alternatively, a fusion protein with another protein can be expressed. Only a protein portion coding for said cDNA can be obtained by cleavage of said fusion protein with a suitable protease.  
     [0016] In the case in which one of the proteins of the present invention is produced in eucaryotic cells, the protein of the present invention can be produced as a transmembrane protein on the cell-membrane surface, when the translation region of said cDNA is subjected to recombination to an expression vector for eucaryotic cells that has a promoter, a splicing region, a poly(A) insertion site, etc., followed by introduction into the eucaryotic cells. The expression vector is exemplified by pKA1, pED6dp2, pCDM8, pSVK3, pMSG, pSVL, pBK-CMV, pBK-RSV, EBV vector, pRS, pYES2, and so on. Examples of eucaryotic cells to be used in general include mammalian culture cells such as simian kidney cells COS7, Chinese hamster ovary cells CHO, etc., budding yeasts, fission yeasts, silkworm cells,  Xenopus laevis  egg cells, and so on, but any eucaryotic cells may be used, provided that they are capable of expressing the present proteins on the membrane surface. The expression vector can be introduced in the eucaryotic cells by methods known in the art such as the electroporation method, the potassium phosphate method, the liposome method, the DEAE-dextran method, and so on.  
     [0017] After one of the proteins of the present invention is expressed in prokaryotic cells or eucaryotic cells, the objective protein can be isolated from the culture and purified by a combination of separation procedures known in the art. Such examples include treatment with a denaturing agent such as urea or a surface-active agent, sonication, enzymatic digestion, salting-out or solvent precipitation, dialysis, centrifugation, ultrafiltration, gel filtration, SDS-PAGE, isoelectric focusing, ion-exchange chromatography, hydrophobic chromatography, affinity chromatography, reverse phase chromatography, and so on.  
     [0018] The proteins of the present invention include peptide fragments (more than 5 amino acid residues) containing any partial amino acid sequence in the amino acid sequences represented by Sequence Nos. 1. to 6. These peptide fragments can be utilized as antigens for preparation of antibodies. Hereupon, among the proteins of the present invention, those having the signal sequence are secreted in the form of maturation proteins on the surface of the cells, after the signal sequences are removed. Therefore, these maturation proteins shall come within the scope of the present invention. The N-terminal amino acid sequences of the maturation proteins can be easily identified by using the method for the cleavage-site determination in a signal sequence [Japanese Patent Kokai Publication No.1996-187100]. Furthermore, some membrane proteins undergo the processing on the cell surface to be converted to the secretory forms. Such proteins or peptides in the secretory forms shall come within the scope of the present invention. When sugar chain-binding sites are present in the amino acid sequences, expression in appropriate eucaryotic cells affords proteins wherein sugar chains are added. Accordingly, such proteins or peptides wherein sugar chains are added shall come within the scope of the present invention.  
     [0019] The DNAs of the present invention include all DNAs coding for the above-mentioned proteins. Said DNAs can be obtained by using a method by chemical synthesis, a method by cDNA cloning, and so on.  
     [0020] The cDNAs of the present invention can be cloned, for example, from cDNA libraries of the human cell origin. These cDNA are synthesized by using as templates poly(A) RNAs extracted from human cells. The human cells may be cells delivered from the human body, for example, by the operation or may be the culture cells. The cDNAs can be synthesized by using any method selected from the Okayama-Berg method [Okayama, H. and Berg, P., Mol. Cell. Biol. 2: 161-170 (1982)], the Gubler-Hoffman method [Gubler, U. and Hoffman, J. Gene 25: 263-269 (1983)], and soon, but it is preferred to use the capping method [Kato, S. et al., Gene 150: 243-250 (1994)], as exemplified in Examples, in order to obtain a full-length clone in an effective manner.  
     [0021] The primary selection of one of the cDNAs coding for the human proteins having transmembrane domains is carried out by sequencing of a partial base sequence of a cDNA clone selected at random from cDNA libraries, sequencing of the amino acid sequence encoded by the base sequence, and recognition of the presence or absence of a hydrophobic site in the resulting N-terminal amino acid sequence region. Next, the secondary selection is carried out by determination of the whole sequence by the sequencing and the protein expression by in vitro translation. Ascertainment of cDNAs of the present invention for encoding the proteins having secretory signal sequences is carried out by using the signal sequence detection method [Yokoyama-Kobayashi, M. et al., Gene 163: 193-196 (1995)]. In other words, the ascertainment for a coding portion of an inserted cDNA fragment to function as a signal sequence is provided by fusing a cDNA fragment coding for the N-terminus of the target protein with a cDNA coding for the protease domain of urokinase and then expressing the resulting cDNA in COS7 cells to detect the urokinase activity in the cell culture medium. On the other hand, in the case in which the urokinase activity is not detectable in the cell medium, the N-terminal region is judged to remain in the membrane.  
     [0022] The cDNAs of the present invention are characterized by containing either of the base sequences represented by Sequence Nos. 7 to 12 or the base sequences represented by Sequence Nos. 13, 15, 17, 19, 21 and 23. Table 1 summarizes the clone number (HP number), the cells affording the cDNA, the total base number of the cDNA, and the number of the amino acid residues of the encoded protein, for each of the cDNAs.  
                               TABLE 1                                   Number of   Number of       Sequence No.   HP No.   Cell   bases   amino acids                                                    1, 7, 13   HP00956   F-2 0S   867   168       2, 8, 14   HP01535   Stomach cancer   720   164       3, 9, 15   HP10089   Liver   566   141       4, 10, 16   HP10216   HT-1080   1078   142       5, 11. 17   HP10420   Stomach cancer   1310   346       6, 12, 18   HP10441   Stomach cancer   781   66                  
 
     [0023] Hereupon, the same clones as the cDNAs of the present invention can be easily obtained by screening of the cDNA libraries constructed from the human cell lines and human tissues utilized in the present invention by the use of an oligonucleotide probe synthesized on the basis of the cDNA base sequence described in any of Sequence Nos. 7. to 12, 13, 15, 17, 19, 21 and 23.  
     [0024] In general, the polymorphism due to the individual difference is frequently observed in human genes. Accordingly, any cDNA that is subjected to insertion or deletion of one or plural nucleotides and/or substitution with other nucleotides in Sequence Nos. 7 to 12, 13, 15, 17, 19, 21 and 23 shall come within the scope of the present invention.  
     [0025] In a similar manner, any protein that is formed by these modifications comprising insertion or deletion of one or plural amino acids and/or substitution with other amino acids shall come within the scope of the present invention, as far as the protein possesses the activity of any protein having the amino acid sequences represented by Sequence Nos. 1 to 6.  
     [0026] The cDNAs of the present invention include cDNA fragments (more than 10 bp) containing any partial base sequence in the base sequences represented by Sequence Nos. 7 to 12 or in the base sequences represented by Sequence Nos. 13, 15, 17, 19, 21 and 23. Also, DNA fragments consisting of a sense chain and an anti-sense chain shall come within this scope. These DNA fragments can be utilized as the probes for the gene diagnosis.  
     [0027] In addition to the activities and uses described above, the polynucleotides and proteins of the present invention may exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).  
     Research Uses and Utilities  
     [0028] The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to “subtract-out” known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a “gene chip” or other support, including for examination of expression patterns; to raise anti-protein antibodiesusing DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791-803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.  
     [0029] The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation. or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.  
     [0030] Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.  
     [0031] Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation “Molecular Cloning: A Laboratory Manual”, 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and “Methods in Enzymology: Guide to Molecular Cloning Techniques”, Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.  
     Nutritional Uses  
     [0032] Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feel of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.  
     Cytokine and Cell Proliferation/Differentiation Activity  
     [0033] A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.  
     [0034] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0035] Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137-3494-3500, 1986; Bertagnolli et al., J. Immunol. 145:1706-1712, 1990; Bertagnoli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., J. Immunol. 149:3778-3783, 1992; Bowman et al., J. Immunol. 152: 1756-1761, 1994.  
     [0036] Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: Polyclonal T cell stimulation, Kruisbeek, A. M. and Shevach, E. M. in Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferony, Schreiber, R. D. In Current Protocols in Immunology. J. E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.  
     [0037] Assays For proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L. S. and Lipsky, P. E. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., J. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A. 80:2931-2938, 1983; Measurement of mouse and human interleukin 6-Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto. 1991; Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11-Bennett, F., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto. 1991; Measurement of mouse and human Interleukin 9- Ciarletta, A., Giannotti, J., Clark, S. C. and Turner, K. J. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.  
     [0038] Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: Current Protocols in Immunology, Edby J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger etal., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J. Immun. 11:405-411, 1981; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988.  
     Immune Stimulating or Suppressing Activity  
     [0039] A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.  
     [0040] Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.  
     [0041] Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.  
     [0042] Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in craft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligands) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e.g., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to aneraize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.  
     [0043] The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.  
     [0044] Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/ipr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).  
     [0045] Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy. Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.  
     [0046] Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.  
     [0047] In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection in vivo.  
     [0048] The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β 2  microglobulin protein or an MHC class IIα chain protein and an MHC class IIβ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.  
     [0049] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0050] Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Edby J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Herrmann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Herrmann et al., J. Immunol. 128:1968-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., Immunol. 137:3494-3500, 1986; Bowmanet al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnolli et al., Cellular Immunclogy 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.  
     [0051] Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: In vitro antibody production, Mond, J. J. and Brunswick, M. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.  
     [0052] Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takaietal., J. Immunol. 140:508-512, 1988; Bertagnolli et al., J. Immunol. 149:3778-3783, 1992.  
     [0053] Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.  
     [0054] Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.  
     [0055] Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551, 1991.  
     Hematoepoiesis Regulating Activity  
     [0056] A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or or factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.  
     [0057] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0058] Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.  
     [0059] Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in.: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et ai., Blood 81:2903-2915, 1993.  
     [0060] Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M. G. In Culture of Hematopoietic Cells. R. I. Freshney, etal. eds. Vol pp.265-268, Wiley-Liss, Inc., New York, N.Y. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I. K. and Briddell, R. A. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 23-39, Wiley-Liss, Inc., New York, N.Y. 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R. E. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 1-21, Wiley-Liss, Inc., New York, N.Y. 1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R. I. Fresnney, et al. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, N.Y. 1994; Long term culture initiating cell assay, Sutherland, F. J. In Culture of Hematopoietic Cells. R. I. Freshney, et al. eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, N.Y. 1994.  
     Tissue Growth Activity  
     [0061] A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.  
     [0062] A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.  
     [0063] A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.  
     [0064] Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.  
     [0065] The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer&#39;s, Parkinson&#39;s disease, Huntington&#39;s disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.  
     [0066] Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.  
     [0067] It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.  
     [0068] A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.  
     [0069] A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.  
     [0070] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0071] Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).  
     [0072] Assays for wound healing activity include, without limitation, those described in: Winter, Epidermal Wound Healing, pps. 71-112 (Maibach, H I and Rovee, D T, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J. Invest. Dermatol 71:382-84 (1978).  
     Activin/Inhibin Activity  
     [0073] A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin-β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, U.S. Pat. No. 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.  
     [0074] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0075] Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., Endocrinology 91:562-572, 1972; Ling et al., Nature 321:779-782, 1986; Vale et al., Nature 321:776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA83:3091-3095, 1986.  
     Chemotactic/Chemokinectic Activity  
     [0076] A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.  
     [0077] A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.  
     [0078] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0079] Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis)consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376, 1995; Lind et al. APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.  
     Hemostatic and Thrombolytic Activity  
     [0080] A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).  
     [0081] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0082] Assay for hemostatic and thrombolyzic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.  
     Receptor/Ligand Activity  
     [0083] A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphonatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selecting, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligend interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.  
     [0084] The activity of a protein of the invention may, among other means, be measured by the following methods:  
     [0085] Suitable assays for receptor-ligand activity include without limitation those described in: Current Protocols in Immunlogy, Ed by J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein etal., J. Exp. Med. 169:149-160 1989; Stoltenborg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.  
     Anti-Inflammatory Activity  
     [0086] Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn&#39;s disease or resulting from over production of ytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphyiaxis and hypersensitivity to an antigenic substance or material.  
     Tumor Inhibition Activity  
     [0087] In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth  
     Other Activities  
     [0088] A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or components); effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.  
     EXAMPLES  
     [0089] The present invention is embodied in more detail by the following examples, but this embodiment is not intended to restrict the present invention. The basic operations and the enzyme reactions with regard to the DNA recombination are carried out according to the literature [“Molecular Cloning. A Laboratory Manual”, Cold Spring Harbor Laboratory, 1989]. Unless otherwise stated, restrictive enzymes and a variety of modification enzymes to be used were those available from TAKARA SHUZO. The manufacturer&#39;s instructions were used for the buffer compositions as well as for the reaction conditions, in each of the enzyme reactions. The cDNA synthesis was carried out according to the literature [Kato, S. et al., Gene 150: 243-250 (1994)].  
     [0090] (1) Preparation of Poly(A) ·  RNA  
     [0091] The fibrosarcoma cell line HT-1080 (ATCC CCL 121), the osteosarcoma cell line U-2 CS (ATCC HTB 96), tissues of stomach cancer delivered by the operation, and the liver were used for human cells to extract mRNAs. The cell lines were incubated by a conventional procedure.  
     [0092] After about 1 g of the human cells was homogenized in 20 ml of a 5.5 M guanidinium thiocyanate solution, a total mRNA was prepared according to the literature [Okayama, H. et al., “Method in Enzymology”, Vol. 164, Academic Press, 1987]. This was subjected to chromatography on oligo (dT)-cellulose column washed with a 20 mM Tris-hydrochloride buffer solution (pH 7.6), 0.5 M NaCl, and 1 mM EDTA to obtain a poly(A) ·  RNA according to the above-described literature.  
     [0093] (2) Construction of cDNA Library  
     [0094] Ten micrograms of the above-mentioned poly(A) ·  RNA were dissolved in a 100 mM Tris-hydrochloride buffer solution (pH 8), one unit of an RNase-free, bacterial alkaline phosphatase was added, and the reaction was run at 37° C. for one hour. After the reaction solution was subjected to phenol extraction, followed by ethanol precipitation, the resulting pellet was dissolved in a solution containing 50 mM sodium acetate (pH 6), 1 mM EDTA, 0.1% 2-mercaptoethanol, and 0.01% Triton X-100. Thereto was added one unit of a tobacco-origin acid pyrophosphatase (Epicentre Technologies) and a total 100 μl volume of the resulting mixture was reacted at 37° C. for one hour. After the reaction solution was subjected to phenol extraction, followed by ethanol precipitation, the resulting pellet was dissolved in water to obtain a solution of a decapped poly(A) ·  RNA.  
     [0095] The decapped poly(A) ·  RNA and 3 nmol of a chimeric DNA-RNA oligonucleotide (5′-dG-dG-dG-dG-dA-dA-dT-dT-dC-dG-dA-G-G-A-3′) were dissolved in a solution containing 50 mM Tris-hydrochloride buffer solution (pH 7.5), 0.5 mM ATP, 5 mM MgCl 2 , 10 mM 2-mercaptoethanol, and 25% polyethylene glycol, whereto was added 50 units of T4RNA ligase and a total 30 μl volume of the resulting mixture was reacted at 20° C. for 12 hours. After the reaction solution was subjected to phenol extraction, followed by ethanol precipitation, the resulting pellet was dissolved in water to obtain a chimeric-oligo-capped poly(A) ·  RNA.  
     [0096] After digestion of vector pKA1 (Japanese Patent Kokai Publication No. 1992-117292) developed by the present inventors with KpnI, about 60 dT tails were added using a terminal transferase. A vector primer to be used below was prepared by digestion of this product with EcoRV to remove a dT tail at one side.  
     [0097] After 6 μg of the previously-prepared chimeric-oligo-capped poly(A) ·  RNA was annealed with 1.2 μg of the vector primer, the resulting product was dissolved in a solution containing 50 mM Tris-hydrochloride buffer solution (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol, and 1.25 mM DNTP (DATP+dCTP+dGTP+dTTP), 200 units of a reverse transcriptase (GIBCO-BRL) were added, and the reaction in a total 20 μl volume was run at 42° C. for one hour. After the reaction solution was subjected to phenol extraction, followed by ethanol precipitation, the resulting pellet was dissolved in a solution containing 50 mM Tris-hydrochloride buffer solution (pH 7.5), 100 mM NaCl, 10 mM MgCl 2 , and 1 mM dithiothreitol. Thereto were added 100 units of EcoRI and a total 20 μl volume of the resulting mixture was reacted at 37° C. for one hour. After the reaction solution was subjected to phenol extraction, followed by ethanol precipitation, the resulting pellet was dissolved in a solution containing 20 mM Tris-hydrochloride buffer solution (pH7.5), 100 mM KCl, 4 mM MgCl 2 , 10 mM (NH 4 ) 2 SO 2 , and 50 μg/ml of the bovine serum albumin. Thereto were added 60 units of an  Escherichia coli  DNA ligase and the resulting mixture was reacted at 16° C. for 16 hours. To the reaction solution were added 2 μl of 2 mM dNTP, 4 units of  Escherichia coli  DNA polymerase I, and 0.1 unit of  Escherichia coli  RNase H and the resulting mixture was reacted at 12° C. for one hour and then at 22° C. for one hour.  
     [0098] Next, the cDNA-synthesis reaction solution was used for transformation of  Escherichia coli  DH12S (GIBCO-BRL). The transformation was carried out by the electroporation method. A portion of the transformant was sprayed on the 2×YT agar culture medium containing 100 μg/ml ampicillin and the mixture was incubated at 37° C. overnight. A colony formed on the agar medium was picked up at random and inoculated on 2 ml of the 2×YT culture medium containing 100 μg/ml ampicillin. After incubation at 37° C. overnight, the culture mixture was centrifuged to separate the mycelia, from which a plasmid DNA was prepared by the alkaline lysis method. The plasmid DNA was subjected to double digestion with EcoRI and NotI, followed by 0.8% agarose gel electrophoresis, to determine the size of the cDNA insert. Furthermore, using the thus-obtained plasmid as a template, the sequence reaction was carried out by using an M13 universal primer labeled with a fluorescent dye and a Taq polymerase (a kit of Applied Biosystems) and then the product was examined with a fluorescent DNA sequencer (Applied Biosystems) to determine an about 400-bp base sequence at the 5′-terminus of the cDNA. The sequence data were filed as the homo/protein cDNA bank database.  
     [0099] (3) Selection of cDNAs Encoding Proteins Having Transmembrane Domains  
     [0100] A base sequence registered in the homo/protein cDNA bank was converted to three frames of amino acid sequences and the presence or absence of an open reading frame (ORF) beginning from the initiation codon was examined. Then, the selection was made for the presence of a signal sequence that is characteristic to a secretory protein at the N-terminus of the portion encoded by the ORF. These clones were sequenced from the both 5′ and 3′ directions by the use of the deletion method using exonuclease III to determine the whole base sequence. The hydrophobicity/hydrophilicity profiles were obtained for proteins encoded by the ORF by the Kyte-Doolittle method [Kyte, J. &amp; Doolittle, R. F., J. Mol. Biol. 157:105-132 (1982)] to examine the presence or absence of a hydrophobic region. In the case in which there is a hydrophobic region of a putative transmembrane domain in the amino acid sequence of an encoded protein, this protein was judged as a membrane protein.  
     [0101] (4) Functional Verification of Secretory Signal Sequence or Transmembrane Domains  
     [0102] It was verified by the method described in the literature [Yokoyama-Kobayashi, M. et al., Gene 163: 193-196 (1995)] that the N-terminal hydrophobic region in the secretory protein clone candidate obtained in the above-mentioned steps functions as a secretory signal sequence. First, the plasmid containing the target cDNA was cleaved at an appropriate restriction enzyme site existing at the downstream of the portion expected for encoding the secretory signal sequence. In the case in which this restriction site was a protruding terminus, the site was blunt-ended by the Klenow treatment or treatment with the mung-bean nuclease. Digestion with HindIlI was further carried out and a DNA fragment containing the SV40 promoter and a cDNA encoding the secretory signal sequence at the downstream of the promoter was separated by agarose gel electrophoresis. The resulting fragment was inserted between HindIII in pSSD3 (DDBJ/EMBL/GenBank Registration No. AB007632) and a restriction enzyme site selected so as to match with the urokinase-coding frame, thereby constructing a vector expressing a fusion protein of the secretory signal sequence of the target cDNA and the urokinase protease domain.  
     [0103] After  Escherichia coli  (host: JM109) bearing the fusion-protein expression vector was incubated at 37° C. for 2 hours in 2 ml of the 2×YT culture medium containing 100 μg/ml of ampicillin, the helper phage M13KO7 (50 μl) was added and the incubation was continued at 37° C. overnight. A supernatant separated by centrifugation underwent precipitation with polyethylene glycol to obtain single-stranded phage particles. These particles were suspended in 100 μl of 1 mM Tris-0.1 mM EDTA, pH 8 (TE). Also, there were used as controls suspensions of single-stranded phage particles prepared in the same manner from pSSD3 and from the vector pKA1-UPA containing a full-length cDNA of urokinase [Yokoyama-Kobavashi, M. et al., Gene 163: 193-196 (1995)].  
     [0104] The culture cells originating from the simian kidney, COS7, were incubated at 37° C. in the presence of 5% CO 2  in the Dulbecco&#39;s modified Eagle&#39;s culture medium (DMEM) containing 10% fetal calf albumin. Into a 6-well plate (Nunc Inc., 3 cm in the well diameter) were inoculated 1×10 5  COS7 cells and incubation was carried out at 37° C. for 22 hours in the presence of 5% CO 2 . After the culture medium was removed, the cell surface was washed with a phosphate buffer solution and then washed again with DMEM containing 50 mM Tris-hydrochloric acid (pH 7.5) (TDMEM). To the resulting cells was added a suspension of 1 μl of the single-stranded phage suspension, 0.6 ml of the DMEM culture medium, and 3 μl of TRANSFECTAM™ (IBF Inc.) and the resulting mixture was incubated at 37° C. for 3 hours in the presence of 5% CO 2 . After the sample solution was removed, the cell surface was washed with TDMEM, 2 ml per well of DMEM containing 10% fetal calf albumin was added, and the incubation was carried out at 37° C. for 2 days in the presence of 5% CO 2 .  
     [0105] To 10 ml of 50 mM phosphate buffer solution (pH 7.4) containing 2% bovine fibrinogen (Miles Inc.), 0.5% agarose, and 1 mM calcium chloride were added 10 units of human thrombin (Mochida Pharmaceutical Co., Ltd.) and the resulting mixture was solidified in a plate of 9 cm in diameter to prepare a fibrin plate. Ten microliters of the culture supernatant of the transfected COS7 cells were spotted on the fibrin plate, which was incubated at 37° C. for 15 hours. In the case in which a clear circle appears on the fibrin plate, it is judged that the cDNA fragment codes for the amino acid sequence functioning as a secretory signal sequence. On the other hand, in case in which a clear circle is not formed, the cells were washed well, then the fibrin sheet was placed on the cells, and incubation was carried our at 37° C. for 15 hours. In case in which a clear portion is formed on the fibrin sheet, it indicates that the urokinase activity was expressed on the cell surface. In other words, the cDNA fragment is judged to code for the transmembrane domains.  
     [0106] (5) Protein Synthesis By in Vitro Translation  
     [0107] The plasmid vector bearing the cDNA of the present invention was used for in vitro transcription/translation with a T N T rabbit reticulocyte lysate kit (Promega). In this case, [ 35 S]methionine was added to label the expression product with a radioisotope. Each of the reactions was carried out according to the protocols attached to the kit. Two micrograms of the plasmid was reacted at 30° C. for 90 minutes in a total 25 μl volume of the reaction solution containing 12.51 μl of T N T rabbit reticulocyte lysate, 0.5 μl of a buffer solution (attached to kit), 2 μl of an amino acid mixture (methionine-free), 2 μl of [ 35 S]methionine (Amersham) (0.37 MBq/μl), 0.5 μl of T7RNA polymerase, and 20 U of RNasin. To 3 μl of the resulting reaction solution was added 2 μl of the SDS sampling buffer (125 mM Tris-hydrochloric acid buffer, pH 6.8, 120 mM 2-mercaptoethanol, 2% SDS solution, 0.025% bromophenol blue, and 20% glycerol) and the resulting mixture was heated at 95° C. for 3 minutes and then subjected to SDS-polyacrylamide gel electrophoresis. The molecular weight of the translation product was determined by carrying out the autoradiograph.  
     [0108] (6) Expression by COS7  
     [0109] Escherichia coli  bearing the expression vector of the protein of the present invention was infected with helper phage M13KO7 and single-stranded phage particles were obtained by the above-mentioned procedure. The thus-obtained phage was used for introducing each expression vector in the culture cells originating from the simian kidney, COS7. After incubation at 37° C. for 2 days in the presence of 5% CO 2 , the incubation was continued for one hour in the culture medium containing [ 35 S]cystine or [ 35 S]methionine. Collection and dissolution of the cells, followed by subjecting to SDS-PAGE, allowed to observe the presence of a band corresponding to the expression product of each protein, which did not exist in the COS7 cells. For instance, HP01535, HP10216 and HP10420 produced respectively bands of 18 kDa, 20 kDa and 76 kDa in the supernatant of the culture medium. HP10441 also produced a band of 7 kDa in the membrane fraction.  
     [0110] (7) Clone Examples  
     [0111] &lt;HP00956&gt; (Sequence Nos. 1, 7, and 13)  
     [0112] Determination of the whole base sequence of the cDNA insert of clone HP00956 obtained from cDNA libraries of the human osteosarcoma cell line revealed the structure consisting of a 211-bp 5′-nontranslation region, a 507-bp ORF, and a 149-bp 3′-nontranslation region. The ORF codes for a protein consisting of 168 amino acid residues and there existed one transmembrane domain at the C-terminal. FIG. 1 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of 20 kDa that was almost consistent with the molecular weight of 18,750 predicted from the ORF.  
     [0113] The search of the protein data base by using the amino acid sequence of the present protein revealed that the protein was analogous to the human H-rev107 protein homologue (SWISS-PROT Accession No. P53816). Table 2 shows the comparison of the amino acid sequence between the human protein of the present invention (HP) and the human H-rev107 protein homologue (HR). Therein, the marks of −, *, and . represent a gap, an amino acid residue identical with the protein of the present invention, and an amino acid residue analogous to the protein of the present invention, respectively. The both proteins possessed a homology of 46.5%.  
                       TABLE 2                          HS   MAFNDCFSLNYPGNPCPGDLIEVFRPGYQHWALYLGDGYVINIAPVDGIP-ASFTSAKSV                            .* ******.*** *.***.*.*****...** .... *. .*..*.       HR           MRAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSA               HS   FSSKALVKMQLLKDVVGNDTYRINNKYDETYPPLPVEEIIKRSEFVIGQEVAYNLLVNNC           ...**.**..** **.*.*.*..***.*..*.*** ..**.*.* ..**** *.*  .**       HR   LTDKAIVKKELLYDVAGSDKYQVNNKHDDKYSPLPCTKIIQRAEELVGQEVLYKLTSENC               HS   EHFVTLLRYGEGVSEQANRAISTVEFVTAAVGVFSFLG-LFPKGQRAKYY           ****. **** . *.*.. .* ... .. .....*..* .*....*.*       HR   EHFVNELRYGVARSDQVRDVITAASVAGMGLAAMSLIGVMFSRNKRQKQ                  
 
     [0114] Furthermore, the search of the GenBank using the base sequences of the present cDNA has revealed the presence of sequences that possessed a homology of 90% or more (for example, Accession No. AA478132) in EST, but, since they are partial sequences, it can not be judged whether or not any of these sequences codes for the same protein as the protein of the present invention.  
     [0115] The human H-rev107 protein is one of proteins which are specifically expressed in H-ras resistant fibroblast cells [Hajnal, A. et al., Oncogene 9: 479-490 (1994)]. Accordingly, the present protein has been considered to be associated with phenotypic expression of cancer cells.  
     [0116] &lt;HP01535&gt; (Sequence Nos. 2, 8, and 15)  
     [0117] Determination of the whole base sequence of the cDNA insert of clone HP01535 obtained from cDNA libraries of human stomach cancer revealed the structure consisting of a 24-bD 5′-nontranslation region, a 495-bp ORF, and a 201-bp 3′-nontranslation region. The ORF codes for a protein consisting or 164 amino acid residues and there existed one transmembrane domain at the C-terminal. FIG. 2 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of 20 kDa that was almost consistent with the molecular weight of 18,179 predicted from the ORF.  
     [0118] The search of the protein data base by using the amino acid sequence of the present protein revealed that the protein was analogous to the human H-rev107 protein homologue (SWISS-PROT Accession No. P53816). Table 3 shows the comparison of the amino acid sequence between the human protein of the present invention (HP) and the human H-rev107 protein homologue (HR). Therein, the marks of −, *, and . represent a gap, an amino acid residue identical with the protein of the present invention, and an amino acid residue analogous to the protein of the present invention, respectively. Both proteins possessed a homology of 51.2% in the entire region.  
                       TABLE 3                          HS   MASPHQEPKPGDLIEIFRLGYEHWALYIGDGYVIHLAPPSEYPGAGSSSVFSVLSNSAEV               *.*.**************  * ***.*.*****.******* .***..**.*.*...* *       HR   MRAPIPEPKPGDLIEIFRPFYRHWAIYVGDGYVVHLAPPSEVAGAGAASVMSALTDKAIV               HS   KRERLEDVVGGCCYRVNNSLDHEYQPRPVEVIISSAKEMVGQKMKYSIVSRNCEHFVTQL           *.* * **.*.  *.***. *..* * * . ** .*.*.***.. *...* ******..*       HR   KKELLYDVAGSDKYQVNNKHDDKYSPLPCTKIIQRAEELVGQEVLYKLTSENCEHFVNEL               HS   RYGKSRCKQVEKAKVEVGVAT-ALGILVVAGCSFAIRRYQKKATA           *** .*..** .. ....**. .*. . . *  *. .. **.        HR   RYGVARSDQVRDVIIAASVAGMGLAAMSLIGVMFSRNKRQKQ                  
 
     [0119] Furthermore, the search of the GenBank using the base sequences of the present cDNA has revealed the presence of sequences that possessed a homology of 90% or more (for example, Accession No. R55646) in EST, but, since they are partial sequences, it can not be judged whether or not any of these sequences codes for the same protein as the protein of the present invention.  
     [0120] The human H-rev107 protein is one of proteins which are specifically expressed in H-ras resistant fibroblast cells [Hajnal, A. et al., Oncogene 9: 479-490 (1994)]. Accordingly, the present protein has been considered to be associated with phenotypic expression of cancer cells.  
     [0121] &lt;HP10089&gt; (Sequence Nos. 3, 9, and 17)  
     [0122] Determination of the whole base sequence of the cDNA insert of clone HP10089 obtained from cDNA libraries of human liver revealed the structure consisting of a 73-bp 5′-nontranslation region, a 426-bp ORF, and a 67-bp 3′-nontranslation region. The ORF codes for a protein consisting of 141 amino acid residues and there existed four transmembrane domains. FIG. 3 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of 14 kDa that was almost consistent with the molecular weight of 14,852 predicted from the ORF.  
     [0123] The search of the protein data base using the amino acid sequence of the present protein has not revealed the presence of any known protein having an analogy. Also, the search of the GenBank using the base sequences of the present cDNA has revealed the presence of sequences that possessed a homology of 90% or more and contained an initiation codon (for example, Accession No. N56722) in EST, but, since they are partial sequences, it can not be judged whether or not any of these sequences codes for the same protein as the protein of the present invention.  
     [0124] &lt;HP10216&gt; (Sequence Nos. 4, 10, and 19)  
     [0125] Determination of the whole base sequence of the cDNA insert of clone HP10216 obtained from cDNA libraries of the human fibrosarcoma cell line HT-1080 revealed the structure consisting of a 4-bp 5′-nontranslation region, a 429-bp ORF, and a 645-bp 3′-nontranslation region. The ORF codes for a protein consisting of 142 amino acid residues and there existed one transmembrane domain. FIG. 4 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of 22 kDa that was larger than the molecular weight of 15,521 predicted from the ORF.  
     [0126] The search of the protein data base using the amino acid sequence of the present protein has not revealed the presence of any known protein having an analogy. Also, the search of the GenBank using the base sequences of the present cDNA has revealed the presence of sequences that possessed a homology of 90% or more and contained an initiation codon (for example, Accession No. AA316462) in EST, but any of the sequences was shorter than the present cDNAs and was not found to contain the initiation codon.  
     [0127] &lt;HP10420&gt; (Sequence Nos. 5, 11, and 21)  
     [0128] Determination of the whole base sequence of the cDNA insert of clone HP10420 obtained from cDNA libraries of human stomach cancer revealed the structure consisting of an 81-bp 5′-nontranslation region, a 1041-bp ORF, and a 188-bp 3′-nontranslation region. The ORF codes for a protein consisting of 346 amino acid residues and there existed a signal-like sequence at the N-terminus and one transmembrane domain at the C-terminus. FIG. 5 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. Introduction of an expression vector, wherein the HindIII-PvuII fragment containing a cDNA portion coding for the N-terminal 34 amino acid residues of the present protein was inserted into the HindIII-SmaI site of pSSD3, into the COS7 cells revealed the urokinase activity in the culture medium to indicate that the present protein is a type-I membrane protein. In vitro translation resulted in formation of a translation product of 39 kDa that was almost consistent with the molecular weight of 35,970 predicted from the ORF. Application of the (−3, −1) rule, a method for predicting the cleavage site in the secretory signal sequence, allows to expect that the maturation protein starts from leucine at position 31.  
     [0129] The search of the protein data base using the amino acid sequence of the present protein has not revealed the presence or any known protein having an analogy. Also, the search of the GenBank using the base sequences of the present cDNA has revealed the presence of sequences that possessed a homology of 90% or more and contained an initiation codon (for example, Accession No. T70513) in EST, but, since they are partial sequences, it can not be judged whether or not any of these sequences codes for the same protein as the protein of the present invention.  
     [0130] &lt;HP10441&gt; (Sequence Nos. 6, 12, and 23)  
     [0131] Determination of the whole base sequence of the cDNA insert of clone HP10441 obtained from cDNA libraries of the human stomach cancer revealed the structure consisting of a 341-bp 5′-nontranslation region, a 201-bp ORF, and a 239-bp 3′-nontranslation region. The ORF codes for a protein consisting of 66 amino acid residues and there existed one transmembrane domain at the C-terminus. FIG. 6 depicts the hydrophobicity/hydrophilicity profile, obtained by the Kyte-Doolittle method, of the present protein. In vitro translation resulted in formation of a translation product of 10 kDa that was almost consistent with the molecular weight of 7,374 predicted from the ORF.  
     [0132] The search of the protein data base using the amino acid sequence of the present protein has revealed the presence of sequences that were analogous to the nematode putative protein F59F4.2 (GenBank Accession No. Z81095). Table 4 shows the comparison of the amino acid sequence between the human protein of the present invention (HP) and the nematode putative protein F59F4.2 (CE). Therein, the marks of −, *, and . represent a gap, an amino acid residue identical with the protein of the present invention, and an amino acid residue analogous to the protein of the present invention, respectively. The both proteins possessed a homology of 52.3% in the entire region.  
                       TABLE 4                          HS   MVAKQRIRMANEKHSKNITQRGNVAKTSRNAPEEKASVGPWLLALFIFVVCGSAIFQIIQ               *..***. .**.. ***...******. . ..*.* ...***..**.*******.*.**.       CE   MAPKQRMTLANKQFSKNVNNRGNVAKSLK-PAEDKYPAAPWLIGLFVFVVCGSVFEIIR               HS   SIRMGM           ..**       CE   YVKMG                  
 
     [0133] Furthermore, the search of the GenBank using the base sequences of the present cDNA has revealed the presence of sequences that possessed a homology of 90% or more and contained the initiation codon. (for example, Accession No. AA232459) in EST, but many sequences were not distinct and the same ORF as that in the present cDNA was not found.  
     INDUSTRIAL APPLICABILITY  
     [0134] The present invention provides human proteins having transmembrane domains and cDNAs coding for these proteins as well as eucaryotic cells expressing said cDNAs. All of the proteins of the present invention exist in the cell membrane, so that they are considered to be proteins controlling the proliferation and the differentiation of the cells. Accordingly, the proteins of the present invention can be employed as pharmaceuticals such as carcinostatic agents relating to the control of the proliferation and the differentiation of the cells or as antigens for preparing antibodies against said proteins. The cDNAs of the present invention can be utilized as probes for the gene diagnosis and gene sources for the gene therapy. Furthermore, the cDNAs can be utilized for large-scale expression of said proteins. Cells, wherein these membrane protein genes are introduced and membrane proteins are expressed in large amounts, can be utilized for detection of the corresponding ligands, screening of novel low-molecular pharmaceuticals, and so on.  
     [0135] The present invention also provides genes corresponding the polynucleotide sequences disclosed herein. “Corresponding genes” are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5′ and 3′ untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An “isolated gene” is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.  
     [0136] Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, Trends Pharmacol. Sci. 15(7): 250-254; Lavarosky et al., 1997, Biochem. Mol. Med. 62(1): 11-22; and Hampel, 1998, Prog. Nucleic Acid Res. Mol. Biol. 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, Bioessays 14 (9): 629-633; Zwaal et al., 1993, Proc. Natl. Acad. Sci. USA 90(16): 7431-7435; Clark et al., 1994, Proc. Natl. Acad. Sci. USA 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al., 1988, Nature 336: 348-352; U.S. Pat. Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development or assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).  
     [0137] Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.  
     [0138] Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.  
     [0139] Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a “species homologue” is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide, as determined by those of still in the art. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.  
     [0140] The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotide which also encode proteins which are identical, homologous, or related to that encoded by the polynucleotides.  
     [0141] The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.  
     [0142] The present invention also includes polynucleotides capable of hybridizing under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.  
                               TABLE 5                               Hybrid       Wash       Stringency   Polynucleotide   Length   Hybridization Temperature   Temperature       Condition   Hybrid   (bp) ‡     and Buffer †     and Buffer †                                                      A   DNA:DNA   ≧50   65° C.: 1 × SSC -or-   65° C.: 0.3 × SSC                   42° C.: 1 × SSC · 50% formamide       B   DNA:DNA   &lt;50   T A *: 1 × SSC   T B *: 1 × SSC       C   DNA:RNA   ≧50   67° C.: 1 × SSC -or-   67° C.: 0.3 × SSC                   45° C.: 1 × SSC · 50% formamide       D   DNA:RNA   &lt;50   T D *: 1 × SSC   T D *: 1 × SSC       E   RNA:RNA   ≧50   70° C.: 1 × SSC -or-   70° C.: 0.3 × SSC                   50° C.: 1 × SSC · 50% formamide       F   RNA:RNA   &lt;50   T F *: 1 × SSC   T F *: 1 × SSC       G   DNA:DNA   ≧50   65° C.: 4 × SSC -or-   65° C.: 1 × SSC                   42° C.: 4 × SSC · 50% formamide       H   DNA:DNA   &lt;50   T H *: 4 × SSC   T H *: 4 × SSC       I   DNA:RNA:   ≧50   67° C.: 4 × SSC -or-   67° C.: 1 × SSC                   45° C.: 4 × SSC · 50% formamide       J   DNA:RNA   &lt;50   T J *: 4 × SSC   T J *: 4 × SSC       K   RNA:RNA   ≧50   70° C.: 4 × SSC -or-   67° C.: 1 × SSC                   50° C.: 4 × SSC · 50% formamide       L   RNA:RNA   &lt;50   T L *: 2 × SSC   T L *: 2 × SSC       M   DNA:DNA   ≧50   50° C.: 4 × SSC -or-   50° C.: 2 × SSC                   40° C.: 6 × SSC · 50% formamide       N   DNA:DNA   &lt;50   T N *: 6 × SSC   T N *: 6 × SSC       O   DNA:RNA   ≧50   55° C.: 4 × SSC -or-   55° C.: 2 × SSC                   42° C.: 6 × SSC · 50% formamide       P   DNA:RNA   &lt;50   T P *: 6 × SSC   T P *: 6 × SSC       Q   RNA:RNA   ≧50   60° C.: 4 × SSC -or-   60° C.: 2 × SSC                   45° C.: 6 × SSC · 50% formamide       R   RNA:RNA   &lt;50   T R *: 4 × SSC   T R *: 4 × SSC                                       # For hybrids between 18 and 49 base pairs in length. T m (° C.) = 81.5 + 16.6(log 10 [Na + ]) + 0.41 (%G + C) − (600/N), where N is the number of bases in the hybrid, and [Na + ] is the concentration of sodium ions in the hybridization buffer ([Na + ] for 1 × SSC = 0.165 M).           
 
     [0143] Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters 9 and 11, and Current Protocols in Molecular Biology, 1995, F. M. Ausubel et al., eds., John Wiley &amp; Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.  
     [0144] Preferably, each such hybridizing polynucleotide has a length that is at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.  
    
     
       
         1 
         
           
             28  
           
           
             1  
             168  
             PRT  
             Homo sapiens  
           
            1 

Met Ala Phe Asn Asp Cys Phe Ser Leu Asn Tyr Pro Gly Asn Pro Cys 
  1               5                  10                  15 

Pro Gly Asp Leu Ile Glu Val Phe Arg Pro Gly Tyr Gln His Trp Ala 
             20                  25                  30 

Leu Tyr Leu Gly Asp Gly Tyr Val Ile Asn Ile Ala Pro Val Asp Gly 
         35                  40                  45 

Ile Pro Ala Ser Phe Thr Ser Ala Lys Ser Val Phe Ser Ser Lys Ala 
     50                  55                  60 

Leu Val Lys Met Gln Leu Leu Lys Asp Val Val Gly Asn Asp Thr Tyr 
 65                  70                  75                  80 

Arg Ile Asn Asn Lys Tyr Asp Glu Thr Tyr Pro Pro Leu Pro Val Glu 
                 85                  90                  95 

Glu Ile Ile Lys Arg Ser Glu Phe Val Ile Gly Gln Glu Val Ala Tyr 
            100                 105                 110 

Asn Leu Leu Val Asn Asn Cys Glu His Phe Val Thr Leu Leu Arg Tyr 
        115                 120                 125 

Gly Glu Gly Val Ser Glu Gln Ala Asn Arg Ala Ile Ser Thr Val Glu 
    130                 135                 140 

Phe Val Thr Ala Ala Val Gly Val Phe Ser Phe Leu Gly Leu Phe Pro 
145                 150                 155                 160 

Lys Gly Gln Arg Ala Lys Tyr Tyr 
                165 

 
           
             2  
             164  
             PRT  
             Homo sapiens  
           
            2 

Met Ala Ser Pro His Gln Glu Pro Lys Pro Gly Asp Leu Ile Glu Ile 
  1               5                  10                  15 

Phe Arg Leu Gly Tyr Glu His Trp Ala Leu Tyr Ile Gly Asp Gly Tyr 
             20                  25                  30 

Val Ile His Leu Ala Pro Pro Ser Glu Tyr Pro Gly Ala Gly Ser Ser 
         35                  40                  45 

Ser Val Phe Ser Val Leu Ser Asn Ser Ala Glu Val Lys Arg Glu Arg 
     50                  55                  60 

Leu Glu Asp Val Val Gly Gly Cys Cys Tyr Arg Val Asn Asn Ser Leu 
 65                  70                  75                  80 

Asp His Glu Tyr Gln Pro Arg Pro Val Glu Val Ile Ile Ser Ser Ala 
                 85                  90                  95 

Lys Glu Met Val Gly Gln Lys Met Lys Tyr Ser Ile Val Ser Arg Asn 
            100                 105                 110 

Cys Glu His Phe Val Thr Gln Leu Arg Tyr Gly Lys Ser Arg Cys Lys 
        115                 120                 125 

Gln Val Glu Lys Ala Lys Val Glu Val Gly Val Ala Thr Ala Leu Gly 
    130                 135                 140 

Ile Leu Val Val Ala Gly Cys Ser Phe Ala Ile Arg Arg Tyr Gln Lys 
145                 150                 155                 160 

Lys Ala Thr Ala 

 
           
             3  
             141  
             PRT  
             Homo sapiens  
           
            3 

Met Ala Pro Lys Val Phe Arg Gln Tyr Trp Asp Ile Pro Asp Gly Thr 
  1               5                  10                  15 

Asp Cys His Arg Lys Ala Tyr Ser Thr Thr Ser Ile Ala Ser Val Ala 
             20                  25                  30 

Gly Leu Thr Ala Ala Ala Tyr Arg Val Thr Leu Asn Pro Pro Gly Thr 
         35                  40                  45 

Phe Leu Glu Gly Val Ala Lys Val Gly Gln Tyr Thr Phe Thr Ala Ala 
     50                  55                  60 

Ala Val Gly Ala Val Phe Gly Leu Thr Thr Cys Ile Ser Ala His Val 
 65                  70                  75                  80 

Arg Glu Lys Pro Asp Asp Pro Leu Asn Tyr Phe Leu Gly Gly Cys Ala 
                 85                  90                  95 

Gly Gly Leu Thr Leu Gly Ala Arg Thr His Asn Tyr Gly Ile Gly Ala 
            100                 105                 110 

Ala Ala Cys Val Tyr Phe Gly Ile Ala Ala Ser Leu Val Lys Met Gly 
        115                 120                 125 

Arg Leu Glu Gly Trp Glu Val Phe Ala Lys Pro Lys Val 
    130                 135                 140 

 
           
             4  
             142  
             PRT  
             Homo sapiens  
           
            4 

Met Ala Ala Ala Val Ala Ala Ala Gly Ala Gly Glu Pro Gln Ser Pro 
  1               5                  10                  15 

Asp Glu Leu Leu Pro Lys Gly Asp Ala Glu Lys Pro Glu Glu Glu Leu 
             20                  25                  30 

Glu Glu Asp Asp Asp Glu Glu Leu Asp Glu Thr Leu Ser Glu Arg Leu 
         35                  40                  45 

Trp Gly Leu Thr Glu Met Phe Pro Glu Arg Val Arg Ser Ala Ala Gly 
     50                  55                  60 

Ala Thr Phe Asp Leu Ser Leu Phe Val Ala Gln Lys Met Tyr Arg Phe 
 65                  70                  75                  80 

Ser Arg Ala Ala Leu Trp Ile Gly Thr Thr Ser Phe Met Ile Leu Val 
                 85                  90                  95 

Leu Pro Val Val Phe Glu Thr Glu Lys Leu Gln Met Glu Gln Gln Gln 
            100                 105                 110 

Gln Leu Gln Gln Arg Gln Ile Leu Leu Gly Pro Asn Thr Gly Leu Ser 
        115                 120                 125 

Gly Gly Met Pro Gly Ala Leu Pro Ser Leu Pro Gly Lys Ile 
    130                 135                 140 

 
           
             5  
             346  
             PRT  
             Homo sapiens  
           
            5 

Met Asp Pro Ala Arg Lys Ala Gly Ala Gln Ala Met Ile Trp Thr Ala 
  1               5                  10                  15 

Gly Trp Leu Leu Leu Leu Leu Leu Arg Gly Gly Ala Gln Ala Leu Glu 
             20                  25                  30 

Cys Tyr Ser Cys Val Gln Lys Ala Asp Asp Gly Cys Ser Pro Asn Lys 
         35                  40                  45 

Met Lys Thr Val Lys Cys Ala Pro Gly Val Asp Val Cys Thr Glu Ala 
     50                  55                  60 

Val Gly Ala Val Glu Thr Ile His Gly Gln Phe Ser Leu Ala Val Arg 
 65                  70                  75                  80 

Gly Cys Gly Ser Gly Leu Pro Gly Lys Asn Asp Arg Gly Leu Asp Leu 
                 85                  90                  95 

His Gly Leu Leu Ala Phe Ile Gln Leu Gln Gln Cys Ala Gln Asp Arg 
            100                 105                 110 

Cys Asn Ala Lys Leu Asn Leu Thr Ser Arg Ala Leu Asp Pro Ala Gly 
        115                 120                 125 

Asn Glu Ser Ala Tyr Pro Pro Asn Gly Val Glu Cys Tyr Ser Cys Val 
    130                 135                 140 

Gly Leu Ser Arg Glu Ala Cys Gln Gly Thr Ser Pro Pro Val Val Ser 
145                 150                 155                 160 

Cys Tyr Asn Ala Ser Asp His Val Tyr Lys Gly Cys Phe Asp Gly Asn 
                165                 170                 175 

Val Thr Leu Thr Ala Ala Asn Val Thr Val Ser Leu Pro Val Arg Gly 
            180                 185                 190 

Cys Val Gln Asp Glu Phe Cys Thr Arg Asp Gly Val Thr Gly Pro Gly 
        195                 200                 205 

Phe Thr Leu Ser Gly Ser Cys Cys Gln Gly Ser Arg Cys Asn Ser Asp 
    210                 215                 220 

Leu Arg Asn Lys Thr Tyr Phe Ser Pro Arg Ile Pro Pro Leu Val Arg 
225                 230                 235                 240 

Leu Pro Pro Pro Glu Pro Thr Thr Val Ala Ser Thr Thr Ser Val Thr 
                245                 250                 255 

Thr Ser Thr Ser Ala Pro Val Arg Pro Thr Ser Thr Thr Lys Pro Met 
            260                 265                 270 

Pro Ala Pro Thr Ser Gln Thr Pro Arg Gln Gly Val Glu His Glu Ala 
        275                 280                 285 

Ser Arg Asp Glu Glu Pro Arg Leu Thr Gly Gly Ala Ala Gly His Gln 
    290                 295                 300 

Asp Arg Ser Asn Ser Gly Gln Tyr Pro Ala Lys Gly Gly Pro Gln Gln 
305                 310                 315                 320 

Pro His Asn Lys Gly Cys Val Ala Pro Thr Ala Gly Leu Ala Ala Leu 
                325                 330                 335 

Leu Leu Ala Val Ala Ala Gly Val Leu Leu 
            340                 345 

 
           
             6  
             66  
             PRT  
             Homo sapiens  
           
            6 

Met Val Ala Lys Gln Arg Ile Arg Met Ala Asn Glu Lys His Ser Lys 
  1               5                  10                  15 

Asn Ile Thr Gln Arg Gly Asn Val Ala Lys Thr Ser Arg Asn Ala Pro 
             20                  25                  30 

Glu Glu Lys Ala Ser Val Gly Pro Trp Leu Leu Ala Leu Phe Ile Phe 
         35                  40                  45 

Val Val Cys Gly Ser Ala Ile Phe Gln Ile Ile Gln Ser Ile Arg Met 
     50                  55                  60 

Gly Met 
 65 

 
           
             7  
             504  
             DNA  
             Homo sapiens  
           
            7 

atggcgttta atgattgctt cagtttgaac taccctggca acccctgccc aggggacttg     60 

atcgaagtgt tccgtcctgg ctatcagcac tgggccctgt acttgggtga tggttacgtt    120 

atcaacatag cacctgtaga tggcattcct gcgtccttta caagcgccaa gtctgtattc    180 

agcagtaagg ccctggtgaa aatgcagctc ttgaaggatg ttgtgggaaa tgacacatac    240 

agaataaaca ataaatacga tgaaacgtac ccccctctcc ctgtggaaga aatcataaag    300 

cggtcagagt ttgtaattgg acaggaggtg gcctataact tacttgtcaa caactgtgaa    360 

cattttgtga cattgcttcg ctatggagaa ggagtttcag agcaggccaa ccgagcgata    420 

agtaccgttg agtttgtgac agctgctgtt ggtgtcttct cattcctggg cttgtttcca    480 

aaaggacaaa gagcaaaata ctat                                           504 

 
           
             8  
             492  
             DNA  
             Homo sapiens  
           
            8 

atggcttcgc cacaccaaga gcccaaacct ggagacctga ttgagatttt ccgccttggc     60 

tatgagcact gggccctgta tataggagat ggctacgtga tccatctggc tcctccaagt    120 

gagtaccccg gggctggctc ctccagtgtc ttctcagtcc tgagcaacag tgcagaggtg    180 

aaacgggagc gcctggaaga tgtggtggga ggctgttgct atcgggtcaa caacagcttg    240 

gaccatgagt accaaccacg gcccgtggag gtgatcatca gttctgcgaa ggagatggtt    300 

ggtcagaaga tgaagtacag tattgtgagc aggaactgtg agcactttgt cacccagctg    360 

agatatggca agtcccgctg taaacaggtg gaaaaggcca aggttgaagt cggtgtggcc    420 

acggcgcttg gaatcctggt tgttgctgga tgctcttttg cgattaggag ataccaaaaa    480 

aaagcgacag cc                                                        492 

 
           
             9  
             423  
             DNA  
             Homo sapiens  
           
            9 

atggcgccga aggtttttcg tcagtactgg gatatccccg atggcaccga ttgccaccgc     60 

aaagcctaca gcaccaccag tattgccagc gtcgctggcc tgaccgccgc tgcctacaga    120 

gtcacactca atcctccggg caccttcctt gaaggagtgg ctaaggttgg acaatacacg    180 

ttcactgcag ctgctgtcgg ggccgtgttt ggcctcacca cctgcatcag cgcccatgtc    240 

cgcgagaagc ccgacgaccc cctgaactac ttcctcggtg gctgcgccgg aggcctgact    300 

ctgggagcac gcacgcacaa ctacgggatt ggcgccgccg cctgcgtgta ctttggcata    360 

gcggcctccc tggtcaagat gggccggctg gagggctggg aggtgtttgc aaaacccaag    420 

gtg                                                                  423 

 
           
             10  
             426  
             DNA  
             Homo sapiens  
           
            10 

atggctgccg ccgtcgctgc tgccggtgca ggggaacccc agtccccgga cgaattgctc     60 

ccgaaaggcg acgcggagaa gcctgaggag gagctggagg aggacgacga tgaggagcta    120 

gatgagaccc tgtcggagag actatggggc ctgacggaga tgtttccgga gagggtccgg    180 

tccgcggccg gagccacttt tgatctttcc ctctttgtgg ctcagaaaat gtacaggttt    240 

tccagggcag ccttgtggat tgggaccact tcctttatga tcctggttct tcccgttgtc    300 

tttgagacgg agaagttgca aatggagcaa cagcagcaac tgcagcagcg gcagatactt    360 

ctaggaccta acacagggct ctcaggagga atgccagggg ctctaccctc acttcctgga    420 

aagatc                                                               426 

 
           
             11  
             1038  
             DNA  
             Homo sapiens  
           
            11 

atggaccccg ccaggaaagc aggtgcccag gccatgatct ggactgcagg ctggctgctg     60 

ctgctgctgc ttcgcggagg agcgcaggcc ctggagtgct acagctgcgt gcagaaagca    120 

gatgacggat gctccccgaa caagatgaag acagtgaagt gcgcgccggg cgtggacgtc    180 

tgcaccgagg ccgtgggggc ggtggagacc atccacggac aattctcgct ggcagtgcgg    240 

ggttgcggtt cgggactccc cggcaagaat gaccgcggcc tggatcttca cgggcttctg    300 

gcgttcatcc agctgcagca atgcgctcag gatcgctgca acgccaagct caacctcacc    360 

tcgcgggcgc tcgacccggc aggtaatgag agtgcatacc cgcccaacgg cgtggagtgc    420 

tacagctgtg tgggcctgag ccgggaggcg tgccagggta catcgccgcc ggtcgtgagc    480 

tgctacaacg ccagcgatca tgtctacaag ggctgcttcg acggcaacgt caccttgacg    540 

gcagctaatg tgactgtgtc cttgcctgtc cggggctgtg tccaggatga attctgcact    600 

cgggatggag taacaggccc agggttcacg ctcagtggct cctgttgcca ggggtcccgc    660 

tgtaactctg acctccgcaa caagacctac ttctcccctc gaatcccacc ccttgtccgg    720 

ctgccccctc cagagcccac gactgtggcc tcaaccacat ctgtcaccac ttctacctcg    780 

gccccagtga gacccacatc caccaccaaa cccatgccag cgccaaccag tcagactccg    840 

agacagggag tagaacacga ggcctcccgg gatgaggagc ccaggttgac tggaggcgcc    900 

gctggccacc aggaccgcag caattcaggg cagtatcctg caaaaggggg gccccagcag    960 

ccccataata aaggctgtgt ggctcccaca gctggattgg cagcccttct gttggccgtg   1020 

gctgctggtg tcctactg                                                 1038 

 
           
             12  
             198  
             DNA  
             Homo sapiens  
           
            12 

atggtcgcca agcaaaggat ccgtatggcc aacgagaagc acagcaagaa catcacccag     60 

cgcggcaacg tcgccaagac ctcgagaaat gcccccgaag agaaggcgtc tgtaggaccc    120 

tggttattgg ctctcttcat ttttgttgtc tgtggttctg caattttcca gattattcaa    180 

agtatcagga tgggcatg                                                  198 

 
           
             13  
             867  
             DNA  
             Homo sapiens  
             
               CDS  
               (212)..(715)  
             
           
            13 

cgtttcagcg tggcggcgct ggtgctggcg ttggccctgg aggacggccc cgagtgatgg     60 

ctggcgcctg cctcccgggt gtctcccggg tacagatgga gtcgtcccgc ggccgccggc    120 

ggcaaggtcg gcagctgcga ggccaagaga gaccccagga cacacacagc tgcctcccgg    180 

tgcgagaaga agaccccggc ttgagagtga g atg gcg ttt aat gat tgc ttc       232 
                                   Met Ala Phe Asn Asp Cys Phe 
                                     1               5 

agt ttg aac tac cct ggc aac ccc tgc cca ggg gac ttg atc gaa gtg      280 
Ser Leu Asn Tyr Pro Gly Asn Pro Cys Pro Gly Asp Leu Ile Glu Val 
         10                  15                  20 

ttc cgt cct ggc tat cag cac tgg gcc ctg tac ttg ggt gat ggt tac      328 
Phe Arg Pro Gly Tyr Gln His Trp Ala Leu Tyr Leu Gly Asp Gly Tyr 
     25                  30                  35 

gtt atc aac ata gca cct gta gat ggc att cct gcg tcc ttt aca agc      376 
Val Ile Asn Ile Ala Pro Val Asp Gly Ile Pro Ala Ser Phe Thr Ser 
 40                  45                  50                  55 

gcc aag tct gta ttc agc agt aag gcc ctg gtg aaa atg cag ctc ttg      424 
Ala Lys Ser Val Phe Ser Ser Lys Ala Leu Val Lys Met Gln Leu Leu 
                 60                  65                  70 

aag gat gtt gtg gga aat gac aca tac aga ata aac aat aaa tac gat      472 
Lys Asp Val Val Gly Asn Asp Thr Tyr Arg Ile Asn Asn Lys Tyr Asp 
             75                  80                  85 

gaa acg tac ccc cct ctc cct gtg gaa gaa atc ata aag cgg tca gag      520 
Glu Thr Tyr Pro Pro Leu Pro Val Glu Glu Ile Ile Lys Arg Ser Glu 
         90                  95                 100 

ttt gta att gga cag gag gtg gcc tat aac tta ctt gtc aac aac tgt      568 
Phe Val Ile Gly Gln Glu Val Ala Tyr Asn Leu Leu Val Asn Asn Cys 
    105                 110                 115 

gaa cat ttt gtg aca ttg ctt cgc tat gga gaa gga gtt tca gag cag      616 
Glu His Phe Val Thr Leu Leu Arg Tyr Gly Glu Gly Val Ser Glu Gln 
120                 125                 130                 135 

gcc aac cga gcg ata agt acc gtt gag ttt gtg aca gct gct gtt ggt      664 
Ala Asn Arg Ala Ile Ser Thr Val Glu Phe Val Thr Ala Ala Val Gly 
                140                 145                 150 

gtc ttc tca ttc ctg ggc ttg ttt cca aaa gga caa aga gca aaa tac      712 
Val Phe Ser Phe Leu Gly Leu Phe Pro Lys Gly Gln Arg Ala Lys Tyr 
            155                 160                 165 
tat taacaattta ccaaagagat attgatattg aaggaatttg ggaggaggaa           765 
Tyr 

aagaaacctg gggtgaatac ttattttcag tgcatcatta ctgttccaga ttcctatgat    825 

ggatggcaga ctctttaata aattgcttac tgatattatc tt                       867 

 
           
             14  
             168  
             PRT  
             Homo sapiens  
           
            14 

Met Ala Phe Asn Asp Cys Phe Ser Leu Asn Tyr Pro Gly Asn Pro Cys 
  1               5                  10                  15 

Pro Gly Asp Leu Ile Glu Val Phe Arg Pro Gly Tyr Gln His Trp Ala 
             20                  25                  30 

Leu Tyr Leu Gly Asp Gly Tyr Val Ile Asn Ile Ala Pro Val Asp Gly 
         35                  40                  45 

Ile Pro Ala Ser Phe Thr Ser Ala Lys Ser Val Phe Ser Ser Lys Ala 
     50                  55                  60 

Leu Val Lys Met Gln Leu Leu Lys Asp Val Val Gly Asn Asp Thr Tyr 
 65                  70                  75                  80 

Arg Ile Asn Asn Lys Tyr Asp Glu Thr Tyr Pro Pro Leu Pro Val Glu 
                 85                  90                  95 

Glu Ile Ile Lys Arg Ser Glu Phe Val Ile Gly Gln Glu Val Ala Tyr 
            100                 105                 110 

Asn Leu Leu Val Asn Asn Cys Glu His Phe Val Thr Leu Leu Arg Tyr 
        115                 120                 125 

Gly Glu Gly Val Ser Glu Gln Ala Asn Arg Ala Ile Ser Thr Val Glu 
    130                 135                 140 

Phe Val Thr Ala Ala Val Gly Val Phe Ser Phe Leu Gly Leu Phe Pro 
145                 150                 155                 160 

Lys Gly Gln Arg Ala Lys Tyr Tyr 
                165 

 
           
             15  
             720  
             DNA  
             Homo sapiens  
             
               CDS  
               (25)..(516)  
             
           
            15 

accagacctc ctcttggctt cgag atg gct tcg cca cac caa gag ccc aaa        51 
                           Met Ala Ser Pro His Gln Glu Pro Lys 
                             1               5 

cct gga gac ctg att gag att ttc cgc ctt ggc tat gag cac tgg gcc       99 
Pro Gly Asp Leu Ile Glu Ile Phe Arg Leu Gly Tyr Glu His Trp Ala 
 10                  15                  20                  25 

ctg tat ata gga gat ggc tac gtg atc cat ctg gct cct cca agt gag      147 
Leu Tyr Ile Gly Asp Gly Tyr Val Ile His Leu Ala Pro Pro Ser Glu 
                 30                  35                  40 

tac ccc ggg gct ggc tcc tcc agt gtc ttc tca gtc ctg agc aac agt      195 
Tyr Pro Gly Ala Gly Ser Ser Ser Val Phe Ser Val Leu Ser Asn Ser 
             45                  50                  55 

gca gag gtg aaa cgg gag cgc ctg gaa gat gtg gtg gga ggc tgt tgc      243 
Ala Glu Val Lys Arg Glu Arg Leu Glu Asp Val Val Gly Gly Cys Cys 
         60                  65                  70 

tat cgg gtc aac aac agc ttg gac cat gag tac caa cca cgg ccc gtg      291 
Tyr Arg Val Asn Asn Ser Leu Asp His Glu Tyr Gln Pro Arg Pro Val 
     75                  80                  85 

gag gtg atc atc agt tct gcg aag gag atg gtt ggt cag aag atg aag      339 
Glu Val Ile Ile Ser Ser Ala Lys Glu Met Val Gly Gln Lys Met Lys 
 90                  95                 100                 105 

tac agt att gtg agc agg aac tgt gag cac ttt gtc acc cag ctg aga      387 
Tyr Ser Ile Val Ser Arg Asn Cys Glu His Phe Val Thr Gln Leu Arg 
                110                 115                 120 

tat ggc aag tcc cgc tgt aaa cag gtg gaa aag gcc aag gtt gaa gtc      435 
Tyr Gly Lys Ser Arg Cys Lys Gln Val Glu Lys Ala Lys Val Glu Val 
            125                 130                 135 

ggt gtg gcc acg gcg ctt gga atc ctg gtt gtt gct gga tgc tct ttt      483 
Gly Val Ala Thr Ala Leu Gly Ile Leu Val Val Ala Gly Cys Ser Phe 
        140                 145                 150 

gcg att agg aga tac caa aaa aaa gcg aca gcc tgaagcagcc acaaaatcct    536 
Ala Ile Arg Arg Tyr Gln Lys Lys Ala Thr Ala 
    155                 160 

gtgttagaag cagctgtggg ggtcccagtg gagatgagcc tcccccatgc ctccagcagc    596 

ctgaccctcg tgccctgtct caggcgttct ctagatcctt tcctctgttt ccctctctcg    656 

ctggcaaaag tatgatctaa ttgaaacaag actgaaggat caataaacag ccatctgccc    716 

cttc                                                                 720 

 
           
             16  
             164  
             PRT  
             Homo sapiens  
           
            16 

Met Ala Ser Pro His Gln Glu Pro Lys Pro Gly Asp Leu Ile Glu Ile 
  1               5                  10                  15 

Phe Arg Leu Gly Tyr Glu His Trp Ala Leu Tyr Ile Gly Asp Gly Tyr 
             20                  25                  30 

Val Ile His Leu Ala Pro Pro Ser Glu Tyr Pro Gly Ala Gly Ser Ser 
         35                  40                  45 

Ser Val Phe Ser Val Leu Ser Asn Ser Ala Glu Val Lys Arg Glu Arg 
     50                  55                  60 

Leu Glu Asp Val Val Gly Gly Cys Cys Tyr Arg Val Asn Asn Ser Leu 
 65                  70                  75                  80 

Asp His Glu Tyr Gln Pro Arg Pro Val Glu Val Ile Ile Ser Ser Ala 
                 85                  90                  95 

Lys Glu Met Val Gly Gln Lys Met Lys Tyr Ser Ile Val Ser Arg Asn 
            100                 105                 110 

Cys Glu His Phe Val Thr Gln Leu Arg Tyr Gly Lys Ser Arg Cys Lys 
        115                 120                 125 

Gln Val Glu Lys Ala Lys Val Glu Val Gly Val Ala Thr Ala Leu Gly 
    130                 135                 140 

Ile Leu Val Val Ala Gly Cys Ser Phe Ala Ile Arg Arg Tyr Gln Lys 
145                 150                 155                 160 

Lys Ala Thr Ala 

 
           
             17  
             566  
             DNA  
             Homo sapiens  
             
               CDS  
               (74)..(496)  
             
           
            17 

gatagccagc cgcggctgcc cttgcgcttc ccgagctggc ggggtccgtg gtgcgggatc     60 

gagattgcgg gct atg gcg ccg aag gtt ttt cgt cag tac tgg gat atc       109 
               Met Ala Pro Lys Val Phe Arg Gln Tyr Trp Asp Ile 
                 1               5                  10 

ccc gat ggc acc gat tgc cac cgc aaa gcc tac agc acc acc agt att      157 
Pro Asp Gly Thr Asp Cys His Arg Lys Ala Tyr Ser Thr Thr Ser Ile 
         15                  20                  25 

gcc agc gtc gct ggc ctg acc gcc gct gcc tac aga gtc aca ctc aat      205 
Ala Ser Val Ala Gly Leu Thr Ala Ala Ala Tyr Arg Val Thr Leu Asn 
     30                  35                  40 

cct ccg ggc acc ttc ctt gaa gga gtg gct aag gtt gga caa tac acg      253 
Pro Pro Gly Thr Phe Leu Glu Gly Val Ala Lys Val Gly Gln Tyr Thr 
 45                  50                  55                  60 

ttc act gca gct gct gtc ggg gcc gtg ttt ggc ctc acc acc tgc atc      301 
Phe Thr Ala Ala Ala Val Gly Ala Val Phe Gly Leu Thr Thr Cys Ile 
                 65                  70                  75 

agc gcc cat gtc cgc gag aag ccc gac gac ccc ctg aac tac ttc ctc      349 
Ser Ala His Val Arg Glu Lys Pro Asp Asp Pro Leu Asn Tyr Phe Leu 
             80                  85                  90 

ggt ggc tgc gcc gga ggc ctg act ctg gga gca cgc acg cac aac tac      397 
Gly Gly Cys Ala Gly Gly Leu Thr Leu Gly Ala Arg Thr His Asn Tyr 
         95                 100                 105 

ggg att ggc gcc gcc gcc tgc gtg tac ttt ggc ata gcg gcc tcc ctg      445 
Gly Ile Gly Ala Ala Ala Cys Val Tyr Phe Gly Ile Ala Ala Ser Leu 
    110                 115                 120 

gtc aag atg ggc cgg ctg gag ggc tgg gag gtg ttt gca aaa ccc aag      493 
Val Lys Met Gly Arg Leu Glu Gly Trp Glu Val Phe Ala Lys Pro Lys 
125                 130                 135                 140 

gtg tgagccctgt gcctgccggg acctccagcc tgcagaatgc gtccagaaat           546 
Val 

aaattctgtg tctgtgtgtg                                                566 

 
           
             18  
             141  
             PRT  
             Homo sapiens  
           
            18 

Met Ala Pro Lys Val Phe Arg Gln Tyr Trp Asp Ile Pro Asp Gly Thr 
  1               5                  10                  15 

Asp Cys His Arg Lys Ala Tyr Ser Thr Thr Ser Ile Ala Ser Val Ala 
             20                  25                  30 

Gly Leu Thr Ala Ala Ala Tyr Arg Val Thr Leu Asn Pro Pro Gly Thr 
         35                  40                  45 

Phe Leu Glu Gly Val Ala Lys Val Gly Gln Tyr Thr Phe Thr Ala Ala 
     50                  55                  60 

Ala Val Gly Ala Val Phe Gly Leu Thr Thr Cys Ile Ser Ala His Val 
 65                  70                  75                  80 

Arg Glu Lys Pro Asp Asp Pro Leu Asn Tyr Phe Leu Gly Gly Cys Ala 
                 85                  90                  95 

Gly Gly Leu Thr Leu Gly Ala Arg Thr His Asn Tyr Gly Ile Gly Ala 
            100                 105                 110 

Ala Ala Cys Val Tyr Phe Gly Ile Ala Ala Ser Leu Val Lys Met Gly 
        115                 120                 125 

Arg Leu Glu Gly Trp Glu Val Phe Ala Lys Pro Lys Val 
    130                 135                 140  
           
             19  
             1078  
             DNA  
             Homo sapiens  
             
               CDS  
               (5)..(430)  
             
           
            19 

agtc atg gct gcc gcc gtc gct gct gcc ggt gca ggg gaa ccc cag tcc      49 
     Met Ala Ala Ala Val Ala Ala Ala Gly Ala Gly Glu Pro Gln Ser 
       1               5                  10                  15 

ccg gac gaa ttg ctc ccg aaa ggc gac gcg gag aag cct gag gag gag       97 
Pro Asp Glu Leu Leu Pro Lys Gly Asp Ala Glu Lys Pro Glu Glu Glu 
                 20                  25                  30 

ctg gag gag gac gac gat gag gag cta gat gag acc ctg tcg gag aga      145 
Leu Glu Glu Asp Asp Asp Glu Glu Leu Asp Glu Thr Leu Ser Glu Arg 
             35                  40                  45 

cta tgg ggc ctg acg gag atg ttt ccg gag agg gtc cgg tcc gcg gcc      193 
Leu Trp Gly Leu Thr Glu Met Phe Pro Glu Arg Val Arg Ser Ala Ala 
         50                  55                  60 

gga gcc act ttt gat ctt tcc ctc ttt gtg gct cag aaa atg tac agg      241 
Gly Ala Thr Phe Asp Leu Ser Leu Phe Val Ala Gln Lys Met Tyr Arg 
     65                  70                  75 

ttt tcc agg gca gcc ttg tgg att ggg acc act tcc ttt atg atc ctg      289 
Phe Ser Arg Ala Ala Leu Trp Ile Gly Thr Thr Ser Phe Met Ile Leu 
 80                  85                  90                  95 

gtt ctt ccc gtt gtc ttt gag acg gag aag ttg caa atg gag caa cag      337 
Val Leu Pro Val Val Phe Glu Thr Glu Lys Leu Gln Met Glu Gln Gln 
                100                 105                 110 

cag caa ctg cag cag cgg cag ata ctt cta gga cct aac aca ggg ctc      385 
Gln Gln Leu Gln Gln Arg Gln Ile Leu Leu Gly Pro Asn Thr Gly Leu 
            115                 120                 125 

tca gga gga atg cca ggg gct cta ccc tca ctt cct gga aag atc          430 
Ser Gly Gly Met Pro Gly Ala Leu Pro Ser Leu Pro Gly Lys Ile 
        130                 135                 140 

tagattgtta ttgctgtttg agctgtctca gtgggataag tttgaaattc aagtgtttga    490 

actgctgata atttggattt tttttttttt ttttaacttt ggcacattga tctatctaaa    550 

cccggtgggg agaattatcc ccacattgtc tcatggaaag actcaacttg caactgtgcc    610 

ctccacacta tccttacttc tgtctccact ctgataccag agtgcagcca tgcagacggt    670 

tattccagct ctggtcaccc gactcctttc accaaattgc tcctaactgg aagatctcac    730 

tttccccttg tggggtagga accgatgcca gtgggaggga tgtgcccctg accattaacg    790 

actgtttttt tttttttttt ttaaagaatg gagttgttgg ggcgggacat gcacacaatg    850 

tgaaacagac aaaatgcatt acacctgtag tgtaaagtgg ccactatgaa tccctatgta    910 

tgagaggagg gaggcaggct gcagcttcag ccacagaatg gggactatgg aagacagcag    970 

gagctcattt cctctgcaca tttcggctgt tagacctgtg tgtgtgttta aaaaaagaga   1030 

agtcagtgct cactttttgt atttaaatat taaaaatgat tccaactg                1078 

 
           
             20  
             142  
             PRT  
             Homo sapiens  
           
            20 

Met Ala Ala Ala Val Ala Ala Ala Gly Ala Gly Glu Pro Gln Ser Pro 
  1               5                  10                  15 

Asp Glu Leu Leu Pro Lys Gly Asp Ala Glu Lys Pro Glu Glu Glu Leu 
             20                  25                  30 

Glu Glu Asp Asp Asp Glu Glu Leu Asp Glu Thr Leu Ser Glu Arg Leu 
         35                  40                  45 

Trp Gly Leu Thr Glu Met Phe Pro Glu Arg Val Arg Ser Ala Ala Gly 
     50                  55                  60 

Ala Thr Phe Asp Leu Ser Leu Phe Val Ala Gln Lys Met Tyr Arg Phe 
 65                  70                  75                  80 

Ser Arg Ala Ala Leu Trp Ile Gly Thr Thr Ser Phe Met Ile Leu Val 
                 85                  90                  95 

Leu Pro Val Val Phe Glu Thr Glu Lys Leu Gln Met Glu Gln Gln Gln 
            100                 105                 110 

Gln Leu Gln Gln Arg Gln Ile Leu Leu Gly Pro Asn Thr Gly Leu Ser 
        115                 120                 125 

Gly Gly Met Pro Gly Ala Leu Pro Ser Leu Pro Gly Lys Ile 
    130                 135                 140 

 
           
             21  
             1310  
             DNA  
             Homo sapiens  
             
               CDS  
               (82)..(1119)  
             
           
            21 

actcatcctg ggctcaggta agagggcccg agctcggagg cggcacatcc aggggggacg     60 

ccaagggagc aggacggagc c atg gac ccc gcc agg aaa gca ggt gcc cag      111 
                        Met Asp Pro Ala Arg Lys Ala Gly Ala Gln 
                          1               5                  10 

gcc atg atc tgg act gca ggc tgg ctg ctg ctg ctg ctg ctt cgc gga      159 
Ala Met Ile Trp Thr Ala Gly Trp Leu Leu Leu Leu Leu Leu Arg Gly 
                 15                  20                  25 

gga gcg cag gcc ctg gag tgc tac agc tgc gtg cag aaa gca gat gac      207 
Gly Ala Gln Ala Leu Glu Cys Tyr Ser Cys Val Gln Lys Ala Asp Asp 
             30                  35                  40 

gga tgc tcc ccg aac aag atg aag aca gtg aag tgc gcg ccg ggc gtg      255 
Gly Cys Ser Pro Asn Lys Met Lys Thr Val Lys Cys Ala Pro Gly Val 
         45                  50                  55 

gac gtc tgc acc gag gcc gtg ggg gcg gtg gag acc atc cac gga caa      303 
Asp Val Cys Thr Glu Ala Val Gly Ala Val Glu Thr Ile His Gly Gln 
     60                  65                  70 

ttc tcg ctg gca gtg cgg ggt tgc ggt tcg gga ctc ccc ggc aag aat      351 
Phe Ser Leu Ala Val Arg Gly Cys Gly Ser Gly Leu Pro Gly Lys Asn 
 75                  80                  85                  90 

gac cgc ggc ctg gat ctt cac ggg ctt ctg gcg ttc atc cag ctg cag      399 
Asp Arg Gly Leu Asp Leu His Gly Leu Leu Ala Phe Ile Gln Leu Gln 
                 95                 100                 105 

caa tgc gct cag gat cgc tgc aac gcc aag ctc aac ctc acc tcg cgg      447 
Gln Cys Ala Gln Asp Arg Cys Asn Ala Lys Leu Asn Leu Thr Ser Arg 
            110                 115                 120 

gcg ctc gac ccg gca ggt aat gag agt gca tac ccg ccc aac ggc gtg      495 
Ala Leu Asp Pro Ala Gly Asn Glu Ser Ala Tyr Pro Pro Asn Gly Val 
        125                 130                 135 

gag tgc tac agc tgt gtg ggc ctg agc cgg gag gcg tgc cag ggt aca      543 
Glu Cys Tyr Ser Cys Val Gly Leu Ser Arg Glu Ala Cys Gln Gly Thr 
    140                 145                 150 

tcg ccg ccg gtc gtg agc tgc tac aac gcc agc gat cat gtc tac aag      591 
Ser Pro Pro Val Val Ser Cys Tyr Asn Ala Ser Asp His Val Tyr Lys 
155                 160                 165                 170 

ggc tgc ttc gac ggc aac gtc acc ttg acg gca gct aat gtg act gtg      639 
Gly Cys Phe Asp Gly Asn Val Thr Leu Thr Ala Ala Asn Val Thr Val 
                175                 180                 185 

tcc ttg cct gtc cgg ggc tgt gtc cag gat gaa ttc tgc act cgg gat      687 
Ser Leu Pro Val Arg Gly Cys Val Gln Asp Glu Phe Cys Thr Arg Asp 
            190                 195                 200 

gga gta aca ggc cca ggg ttc acg ctc agt ggc tcc tgt tgc cag ggg      735 
Gly Val Thr Gly Pro Gly Phe Thr Leu Ser Gly Ser Cys Cys Gln Gly 
        205                 210                 215 

tcc cgc tgt aac tct gac ctc cgc aac aag acc tac ttc tcc cct cga      783 
Ser Arg Cys Asn Ser Asp Leu Arg Asn Lys Thr Tyr Phe Ser Pro Arg 
    220                 225                 230 

atc cca ccc ctt gtc cgg ctg ccc cct cca gag ccc acg act gtg gcc      831 
Ile Pro Pro Leu Val Arg Leu Pro Pro Pro Glu Pro Thr Thr Val Ala 
235                 240                 245                 250 

tca acc aca tct gtc acc act tct acc tcg gcc cca gtg aga ccc aca      879 
Ser Thr Thr Ser Val Thr Thr Ser Thr Ser Ala Pro Val Arg Pro Thr 
                255                 260                 265 

tcc acc acc aaa ccc atg cca gcg cca acc agt cag act ccg aga cag      927 
Ser Thr Thr Lys Pro Met Pro Ala Pro Thr Ser Gln Thr Pro Arg Gln 
            270                 275                 280 

gga gta gaa cac gag gcc tcc cgg gat gag gag ccc agg ttg act gga      975 
Gly Val Glu His Glu Ala Ser Arg Asp Glu Glu Pro Arg Leu Thr Gly 
        285                 290                 295 

ggc gcc gct ggc cac cag gac cgc agc aat tca ggg cag tat cct gca     1023 
Gly Ala Ala Gly His Gln Asp Arg Ser Asn Ser Gly Gln Tyr Pro Ala 
    300                 305                 310 

aaa ggg ggg ccc cag cag ccc cat aat aaa ggc tgt gtg gct ccc aca     1071 
Lys Gly Gly Pro Gln Gln Pro His Asn Lys Gly Cys Val Ala Pro Thr 
315                 320                 325                 330 

gct gga ttg gca gcc ctt ctg ttg gcc gtg gct gct ggt gtc cta ctg     1119 
Ala Gly Leu Ala Ala Leu Leu Leu Ala Val Ala Ala Gly Val Leu Leu 
                335                 340                 345 

tgagcttctc cacctggaaa tttccctctc acctacttct ctggccctgg gtacccctct   1179 

tctcatcact tcctgttccc accactggac tgggctggcc cagcccctgt ttttccaaca   1239 

ttccccagta tccccagctt ctgctgcgct ggtttgcggc tttgggaaat aaaataccgt   1299 

tgtatatatt c                                                        1310 

 
           
             22  
             346  
             PRT  
             Homo sapiens  
           
            22 

Met Asp Pro Ala Arg Lys Ala Gly Ala Gln Ala Met Ile Trp Thr Ala 
  1               5                  10                  15 

Gly Trp Leu Leu Leu Leu Leu Leu Arg Gly Gly Ala Gln Ala Leu Glu 
             20                  25                  30 

Cys Tyr Ser Cys Val Gln Lys Ala Asp Asp Gly Cys Ser Pro Asn Lys 
         35                  40                  45 

Met Lys Thr Val Lys Cys Ala Pro Gly Val Asp Val Cys Thr Glu Ala 
     50                  55                  60 

Val Gly Ala Val Glu Thr Ile His Gly Gln Phe Ser Leu Ala Val Arg 
 65                  70                  75                  80 

Gly Cys Gly Ser Gly Leu Pro Gly Lys Asn Asp Arg Gly Leu Asp Leu 
                 85                  90                  95 

His Gly Leu Leu Ala Phe Ile Gln Leu Gln Gln Cys Ala Gln Asp Arg 
            100                 105                 110 

Cys Asn Ala Lys Leu Asn Leu Thr Ser Arg Ala Leu Asp Pro Ala Gly 
        115                 120                 125 

Asn Glu Ser Ala Tyr Pro Pro Asn Gly Val Glu Cys Tyr Ser Cys Val 
    130                 135                 140 

Gly Leu Ser Arg Glu Ala Cys Gln Gly Thr Ser Pro Pro Val Val Ser 
145                 150                 155                 160 

Cys Tyr Asn Ala Ser Asp His Val Tyr Lys Gly Cys Phe Asp Gly Asn 
                165                 170                 175 

Val Thr Leu Thr Ala Ala Asn Val Thr Val Ser Leu Pro Val Arg Gly 
            180                 185                 190 

Cys Val Gln Asp Glu Phe Cys Thr Arg Asp Gly Val Thr Gly Pro Gly 
        195                 200                 205 

Phe Thr Leu Ser Gly Ser Cys Cys Gln Gly Ser Arg Cys Asn Ser Asp 
    210                 215                 220 

Leu Arg Asn Lys Thr Tyr Phe Ser Pro Arg Ile Pro Pro Leu Val Arg 
225                 230                 235                 240 

Leu Pro Pro Pro Glu Pro Thr Thr Val Ala Ser Thr Thr Ser Val Thr 
                245                 250                 255 

Thr Ser Thr Ser Ala Pro Val Arg Pro Thr Ser Thr Thr Lys Pro Met 
            260                 265                 270 

Pro Ala Pro Thr Ser Gln Thr Pro Arg Gln Gly Val Glu His Glu Ala 
        275                 280                 285 

Ser Arg Asp Glu Glu Pro Arg Leu Thr Gly Gly Ala Ala Gly His Gln 
    290                 295                 300 

Asp Arg Ser Asn Ser Gly Gln Tyr Pro Ala Lys Gly Gly Pro Gln Gln 
305                 310                 315                 320 

Pro His Asn Lys Gly Cys Val Ala Pro Thr Ala Gly Leu Ala Ala Leu 
                325                 330                 335 

Leu Leu Ala Val Ala Ala Gly Val Leu Leu 
            340                 345 

 
           
             23  
             781  
             DNA  
             Homo sapiens  
             
               CDS  
               (342)..(539)  
             
           
            23 

caattcccgt tgttgcgttg cgtttccttc ctctttcact ccgcgctcac ggcggcggcc     60 

aaagcggcgg cgacggcggc gcgagaacga cccggcggcc agttctcttc ctcctgcgca    120 

cctgccctgc tcggtcagtc agtcggcggc cggcgcccgg cttgtgctca gacctcgcgc    180 

ttgcggcgcc caggcccagc ggccgtagct agcgtctggc ctgagaacct cggcgctccg    240 

gcggcgcggg caccacgagc ggagcctcgc agcggctcca gaggaggcag gcgagtgagc    300 

gagtccgagg ggtggccggg gcaggtggtg gcgccgcgaa g atg gtc gcc aag caa    356 
                                              Met Val Ala Lys Gln 
                                                1               5 

agg atc cgt atg gcc aac gag aag cac agc aag aac atc acc cag cgc      404 
Arg Ile Arg Met Ala Asn Glu Lys His Ser Lys Asn Ile Thr Gln Arg 
                 10                  15                  20 

ggc aac gtc gcc aag acc tcg aga aat gcc ccc gaa gag aag gcg tct      452 
Gly Asn Val Ala Lys Thr Ser Arg Asn Ala Pro Glu Glu Lys Ala Ser 
             25                  30                  35 

gta gga ccc tgg tta ttg gct ctc ttc att ttt gtt gtc tgt ggt tct      500 
Val Gly Pro Trp Leu Leu Ala Leu Phe Ile Phe Val Val Cys Gly Ser 
         40                  45                  50 

gca att ttc cag att att caa agt atc agg atg ggc atg tgaagtgact       549 
Ala Ile Phe Gln Ile Ile Gln Ser Ile Arg Met Gly Met 
     55                  60                  65 

gaccttaaga tgtttccatt ctcctgtgaa ttttaacttg aactcattcc tgatgtttga    609 

taccctggtt gaaaacaatt cagtaaagca tcctgcctca gaatgacttt cctatcatgc    669 

ttcatgtgtc attccaaggt ttcttcatga gtcattccaa gttttctagt ccataccaca    729 

gtgccttgca aaaaacacca catgaataaa gcaataaaat ttgattgtta ag            781 

 
           
             24  
             66  
             PRT  
             Homo sapiens  
           
            24 

Met Val Ala Lys Gln Arg Ile Arg Met Ala Asn Glu Lys His Ser Lys 
  1               5                  10                  15 

Asn Ile Thr Gln Arg Gly Asn Val Ala Lys Thr Ser Arg Asn Ala Pro 
             20                  25                  30 

Glu Glu Lys Ala Ser Val Gly Pro Trp Leu Leu Ala Leu Phe Ile Phe 
         35                  40                  45 

Val Val Cys Gly Ser Ala Ile Phe Gln Ile Ile Gln Ser Ile Arg Met 
     50                  55                  60 

Gly Met 
 65 

 
           
             25  
             14  
             DNA  
             Artificial Sequence  
             
               Description of Artificial Sequence chimeric 
      DNA-RNA oligonucleotide  
             
           
            25 

ggggaattcg agga                                                       14 

 
           
             26  
             162  
             PRT  
             Homo sapiens  
           
            26 

Met Arg Ala Pro Ile Pro Glu Pro Lys Pro Gly Asp Leu Ile Glu Ile 
  1               5                  10                  15 

Phe Arg Pro Phe Tyr Arg His Trp Ala Ile Tyr Val Gly Asp Gly Tyr 
             20                  25                  30 

Val Val His Leu Ala Pro Pro Ser Glu Val Ala Gly Ala Gly Ala Ala 
         35                  40                  45 

Ser Val Met Ser Ala Leu Thr Asp Lys Ala Ile Val Lys Lys Glu Leu 
     50                  55                  60 

Leu Tyr Asp Val Ala Gly Ser Asp Lys Tyr Gln Val Asn Asn Lys His 
 65                  70                  75                  80 

Asp Asp Lys Tyr Ser Pro Leu Pro Cys Thr Lys Ile Ile Gln Arg Ala 
                 85                  90                  95 

Glu Glu Leu Val Gly Gln Glu Val Leu Tyr Lys Leu Thr Ser Glu Asn 
            100                 105                 110 

Cys Glu His Phe Val Asn Glu Leu Arg Tyr Gly Val Ala Arg Ser Asp 
        115                 120                 125 

Gln Val Arg Asp Val Ile Ile Ala Ala Ser Val Ala Gly Met Gly Leu 
    130                 135                 140 

Ala Ala Met Ser Leu Ile Gly Val Met Phe Ser Arg Asn Lys Arg Gln 
145                 150                 155                 160 

Lys Gln 

 
           
             27  
             162  
             PRT  
             Homo sapiens  
           
            27 

Met Arg Ala Pro Ile Pro Glu Pro Lys Pro Gly Asp Leu Ile Glu Ile 
  1               5                  10                  15 

Phe Arg Pro Phe Tyr Arg His Trp Ala Ile Tyr Val Gly Asp Gly Tyr 
             20                  25                  30 

Val Val His Leu Ala Pro Pro Ser Glu Val Ala Gly Ala Gly Ala Ala 
         35                  40                  45 

Ser Val Met Ser Ala Leu Thr Asp Lys Ala Ile Val Lys Lys Glu Leu 
     50                  55                  60 

Leu Tyr Asp Val Ala Gly Ser Asp Lys Tyr Gln Val Asn Asn Lys His 
 65                  70                  75                  80 

Asp Asp Lys Tyr Ser Pro Leu Pro Cys Thr Lys Ile Ile Gln Arg Ala 
                 85                  90                  95 

Glu Glu Leu Val Gly Gln Glu Val Leu Tyr Lys Leu Thr Ser Glu Asn 
            100                 105                 110 

Cys Glu His Phe Val Asn Glu Leu Arg Tyr Gly Val Ala Arg Ser Asp 
        115                 120                 125 

Gln Val Arg Asp Val Ile Ile Ala Ala Ser Val Ala Gly Met Gly Leu 
    130                 135                 140 

Ala Ala Met Ser Leu Ile Gly Val Met Phe Ser Arg Asn Lys Arg Gln 
145                 150                 155                 160 

Lys Gln 

 
           
             28  
             64  
             PRT  
             Nematode  
           
            28 

Met Ala Pro Lys Gln Arg Met Thr Leu Ala Asn Lys Gln Phe Ser Lys 
  1               5                  10                  15 

Asn Val Asn Asn Arg Gly Asn Val Ala Lys Ser Leu Lys Pro Ala Glu 
             20                  25                  30 

Asp Lys Tyr Pro Ala Ala Pro Trp Leu Ile Gly Leu Phe Val Phe Val 
         35                  40                  45 

Val Cys Gly Ser Ala Val Phe Glu Ile Ile Arg Tyr Val Lys Met Gly 
     50                  55                  60